•
Jun 30, 2020

Chemours Q2 2020 Earnings Report

Chemours' Q2 2020 results reflect disciplined execution of cash generation strategy amidst COVID-19 impact.

Key Takeaways

Chemours reported net sales of $1.1 billion and net income of $24 million, with an EPS of $0.15. Adjusted EPS was $0.18. The company's free cash flow was $50 million, a $167 million improvement from the prior year. The results were impacted by lower volumes across all segments due to COVID-19.

Net Sales of $1.1 billion.

Net Income of $24 million, with EPS of $0.15.

Adjusted Net Income of $30 million, with Adjusted EPS of $0.18.

Free Cash Flow of $50 million, a $167 million improvement from prior year.

Total Revenue
$1.09B
Previous year: $1.41B
-22.4%
EPS
$0.18
Previous year: $0.72
-75.0%
Gross Profit
$199M
Previous year: $323M
-38.4%
Cash and Equivalents
$1.03B
Previous year: $630M
+63.7%
Free Cash Flow
$50M
Previous year: -$118M
-142.4%
Total Assets
$7.03B
Previous year: $7.43B
-5.4%

Chemours

Chemours

Chemours Revenue by Segment

Forward Guidance

The outlook for the second half, while improving, remains unclear. Chemours remains focused on the execution of their short-term response plan and long-term strategy.

Positive Outlook

  • Focus on short-term response plan.
  • Focus on long-term strategy.
  • Commitment to customer partnership.
  • Aim to deliver full potential of value proposition.
  • Prioritizing customer success.

Challenges Ahead

  • Unclear outlook for the second half of 2020.
  • Navigating uncertain times.
  • Dependence on market conditions.
  • Potential impact of COVID-19.
  • Global economic uncertainty.